The company's financial distress has intensified, with the operating profit before depreciation, interest, and tax (PBDIT) excluding other income plunging to a seven-quarter low of -₹0.74 crores in Q4 FY26. This represents a stark deterioration from the already negative -₹0.54 crores recorded in Q3 FY26. The operating margin has collapsed to -104.23%, highlighting fundamental issues in the company's core business operations.
Trading at ₹37.50 as of May 27, 2026, the stock has declined 0.85% in the latest session and sits 43.57% below its 52-week high of ₹66.45. With a proprietary Mojo score of just 17 out of 100 and a "Strong Sell" advisory, the investment case appears increasingly challenged by persistent operational losses and deteriorating financial metrics.
Financial Performance: Accelerating Revenue Decline
Salem Erode Investments' top-line performance in Q4 FY26 continued its troubling trajectory, with net sales declining 13.41% quarter-on-quarter to ₹0.71 crores from ₹0.82 crores in Q3 FY26. The year-on-year comparison paints an even grimmer picture, with revenues falling 20.22% from ₹0.89 crores in Q4 FY25. This marks the fourth consecutive quarter of sequential revenue contraction, underscoring the company's inability to generate sustainable business activity.
| Quarter | Net Sales (₹ Cr) | QoQ Change | Net Profit (₹ Cr) | Operating Margin |
|---|---|---|---|---|
| Mar'26 | 0.71 | -13.41% | -1.40 | -104.23% |
| Dec'25 | 0.82 | -7.87% | -1.26 | -65.85% |
| Sep'25 | 0.89 | -18.35% | -1.20 | -57.30% |
| Jun'25 | 1.09 | +22.47% | -0.99 | -23.85% |
| Mar'25 | 0.89 | +9.88% | -1.21 | -53.93% |
| Dec'24 | 0.81 | -32.50% | -1.36 | -48.15% |
| Sep'24 | 1.20 | — | -0.85 | +6.67% |
The company's cost structure remains deeply problematic. Employee costs in Q4 FY26 stood at ₹0.99 crores, exceeding the quarter's entire revenue of ₹0.71 crores by 39.44%. This fundamental mismatch between income generation and fixed costs has rendered the business model unsustainable. Interest expenses of ₹0.45 crores and depreciation of ₹0.30 crores further compound the profitability challenges, resulting in a pre-tax loss of ₹1.46 crores for the quarter.
The profit after tax margin deteriorated to -197.18% in Q4 FY26, compared to -153.66% in Q3 FY26, indicating that for every rupee of revenue generated, the company incurs losses of nearly two rupees. This unsustainable trajectory raises serious questions about the company's ability to continue operations without significant restructuring or capital infusion.
Critical Warning: Unsustainable Cost Structure
Employee costs alone exceed total revenue by 39.44%, creating an impossible operational equation. With operating losses deepening to -₹0.74 crores in Q4 FY26 and seven consecutive quarters of negative profitability, the company faces existential challenges. Immediate and drastic cost rationalisation is imperative for survival.
Operational Distress: Balance Sheet Under Strain
Salem Erode Investments' balance sheet reflects a company under considerable stress. As of March 2018 (the most recent annual data available), shareholder funds stood at ₹17.06 crores, with reserves and surplus of ₹15.91 crores. However, the accumulated losses over the past seven quarters have likely eroded a significant portion of this equity base, raising concerns about net worth adequacy.
The company's return on equity has collapsed to -27.09% on a trailing basis, whilst the average ROE over the longer term stands at a meagre 1.13%. This represents one of the weakest capital efficiency metrics in the NBFC sector, where healthy players typically deliver ROE in the 12-18% range. The negative ROE indicates that the company is destroying shareholder value with each passing quarter.
Return on capital employed (ROCE) paints an equally concerning picture at -19.50%, suggesting that the company's core operations are incapable of generating positive returns on the capital deployed. The debt-to-equity ratio of 0.06 appears benign on the surface, but the absence of meaningful debt likely reflects lenders' unwillingness to extend credit to a persistently loss-making entity rather than prudent financial management.
Quality Metrics: Below Average Assessment
Salem Erode Investments carries a "Below Average" quality grade, reflecting weak long-term financial performance. The company's five-year sales growth of 10.90% is overshadowed by a catastrophic five-year EBIT growth of -213.42%, indicating severe and sustained operational deterioration. With an average ROE of just 1.13% and institutional holdings of merely 0.73%, the company lacks both operational excellence and investor confidence.
Valuation Analysis: Risky Despite Micro-Cap Status
Salem Erode Investments trades at a price-to-book value of 2.52x, a seemingly modest multiple that belies the company's fundamental challenges. With the stock loss-making on a trailing twelve-month basis, traditional price-to-earnings metrics are not applicable. The company's valuation grade has been classified as "Risky" by market assessment frameworks, having oscillated between "Risky" and "Expensive" designations over the past several months.
The enterprise value-to-sales multiple of 11.30x appears extraordinarily elevated for a company generating minimal revenue and posting consistent losses. This suggests that the current market capitalisation of ₹42.00 crores may not adequately reflect the deteriorating operational reality. With book value per share at ₹16.90 and the current market price at ₹37.50, the stock trades at a 122% premium to book value despite destroying shareholder wealth.
| Valuation Metric | Current Value | Assessment |
|---|---|---|
| P/E Ratio (TTM) | NA (Loss Making) | Not Applicable |
| Price to Book Value | 2.52x | Premium to Book |
| EV/Sales | 11.30x | Extremely Elevated |
| EV/EBITDA | -23.30x | Negative (Loss-making) |
| Dividend Yield | NA | No Dividends |
The absence of dividend payments reflects the company's inability to generate distributable profits. For investors seeking income or capital appreciation, Salem Erode Investments offers neither, making the investment proposition fundamentally challenged at current valuations.
Peer Comparison: Lagging Industry Standards
When benchmarked against peers in the NBFC space, Salem Erode Investments' underperformance becomes starkly evident. The company's ROE of 1.13% trails significantly behind sector participants such as Sugal & Damani (9.67% ROE) and AD Manum Finance (9.21% ROE). Even amongst smaller NBFCs, Salem Erode's capital efficiency ranks at the bottom of the peer group.
| Company | P/E Ratio | P/BV Ratio | ROE (%) | Debt/Equity |
|---|---|---|---|---|
| Salem Erode Inv. | NA (Loss Making) | 2.52 | 1.13% | 0.06 |
| Nam Securities | 235.85 | 4.04 | 2.85% | 0.02 |
| AD Manum Finance | 4.29 | 0.50 | 9.21% | 0.26 |
| Kiduja India | 1.71 | -1.89 | 0.00% | -1.51 |
| Srestha Finvest | NA (Loss Making) | 0.27 | 3.70% | 0.29 |
| Sugal & Damani | 8.37 | 1.47 | 9.67% | 0.02 |
The price-to-book valuation of 2.52x appears elevated relative to profitable peers like AD Manum Finance (0.50x P/BV) and Sugal & Damani (1.47x P/BV), both of which generate substantially higher returns on equity. This valuation disconnect suggests that the market has not fully priced in the severity of Salem Erode's operational challenges, creating potential downside risk as fundamentals continue to deteriorate.
Shareholding Pattern: Stable but Concerning Concentration
The shareholding structure of Salem Erode Investments has remained remarkably static over the past five quarters, with promoter holding steady at 75.00% and no sequential changes across any investor category. ICL Fincorp Limited maintains the entire promoter stake, demonstrating commitment but also raising questions about the lack of external investor interest.
| Shareholder Category | Mar'26 | Dec'25 | Sep'25 | Jun'25 | Mar'25 |
|---|---|---|---|---|---|
| Promoter Holding | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% |
| FII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Mutual Fund Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Other DII Holdings | 0.73% | 0.73% | 0.73% | 0.73% | 0.73% |
| Non-Institutional | 24.27% | 24.27% | 24.27% | 24.27% | 24.27% |
The complete absence of foreign institutional investors (FIIs) and mutual funds signals a lack of institutional confidence in the company's prospects. With total institutional holdings at a mere 0.73%, Salem Erode Investments operates outside the purview of professional fund managers who typically conduct rigorous due diligence. The 24.27% non-institutional holding represents retail investors who may lack the resources to fully assess the company's deteriorating fundamentals.
Positively, there is no promoter pledging, indicating that the controlling shareholders have not leveraged their stake for external financing. However, the static nature of the shareholding pattern over five consecutive quarters suggests limited liquidity and an absence of meaningful investor activity, whether buying or selling.
Investment Thesis: Multiple Red Flags
The investment case for Salem Erode Investments is severely compromised by a confluence of negative factors across all key parameters. The company's Mojo score of 17 out of 100 places it firmly in "Strong Sell" territory, reflecting deep-seated operational and financial challenges that show no signs of reversal.
From a quality perspective, the "Below Average" grade is supported by weak long-term metrics: whilst five-year sales growth of 10.90% appears reasonable, the catastrophic five-year EBIT growth of -213.42% reveals that top-line expansion has come at the cost of profitability destruction. The average ROE of 1.13% ranks amongst the weakest in the NBFC sector, indicating fundamental issues with the business model's ability to generate returns on shareholder capital.
The financial trend assessment classifies the company as "Flat" for the most recent quarter, though this understates the severity of the situation. With operating profit before interest, depreciation, and tax at a seven-quarter low and profit before tax (excluding other income) also at multi-quarter lows, the trajectory is decidedly negative rather than flat.
Technical indicators add another layer of concern, with the stock characterised as "Mildly Bearish." Trading 43.57% below its 52-week high and showing consistent underperformance, the technical picture reinforces the fundamental weakness. The valuation grade of "Risky" aptly captures the elevated risk-reward profile, with limited upside potential and substantial downside vulnerability.
Key Strengths and Risk Factors
Limited Positives
- Low Leverage: Debt-to-equity ratio of 0.06 provides minimal financial risk from borrowings
- Stable Promoter Holding: 75% promoter stake with no pledging indicates commitment
- Modest Five-Year Sales Growth: 10.90% sales CAGR shows some revenue generation capability
- Micro-Cap Liquidity: Small market cap of ₹42 crores allows for easier exit if needed
Critical Risk Factors
- Persistent Losses: Seven consecutive quarters of negative profitability with no turnaround in sight
- Collapsing Margins: Operating margin of -104.23% indicates unsustainable cost structure
- Revenue Decline: Sequential 13.41% QoQ and 20.22% YoY revenue contraction
- Negative ROE: -27.09% ROE represents severe shareholder value destruction
- Employee Cost Mismatch: Wage bill exceeds total revenue by 39.44%
- Zero Institutional Interest: Complete absence of FII and mutual fund participation
- Weak Long-Term Profitability: Five-year EBIT growth of -213.42% shows structural decline
- Below Average Quality Grade: Fundamental weakness across multiple parameters
Outlook: What to Monitor
Potential Catalysts (Highly Unlikely)
- Drastic cost restructuring programme to align expenses with revenue
- Strategic pivot to higher-margin business lines
- Capital infusion from promoters to stabilise balance sheet
- Revenue acceleration through new business initiatives
Red Flags to Watch
- Further sequential revenue declines in Q1 FY27
- Continued operating margin deterioration below -100%
- Erosion of shareholder funds below regulatory thresholds
- Inability to reduce employee costs in line with revenue
- Any increase in debt levels given negative cash generation
- Promoter stake reduction or pledging emergence
The Verdict: Exit Recommended
Score: 17/100
For Fresh Investors: Avoid entirely. Salem Erode Investments exhibits all the hallmarks of a distressed company with seven consecutive quarters of losses, negative operating margins exceeding 100%, and deteriorating revenues. The unsustainable cost structure and absence of any turnaround catalysts make this an unsuitable investment at any price.
For Existing Holders: Exit at the earliest opportunity. With ROE at -27.09%, operating losses deepening, and no credible path to profitability, continuing to hold represents ongoing capital destruction. The stock's 43.57% decline from its 52-week high may continue as fundamentals deteriorate further.
Fair Value Estimate: ₹12-15 (60-68% downside from current levels), reflecting the company's negative earnings trajectory and below-average quality grade.
Note— ROCE = (EBIT - Other income)/(Capital Employed - Cash - Current Investments)
⚠️ Investment Disclaimer
This article is for educational and informational purposes only and should not be construed as financial advice. Investors should conduct their own due diligence, consider their risk tolerance and investment objectives, and consult with a qualified financial adviser before making any investment decisions. Past performance is not indicative of future results, and all investments carry inherent risks including the potential loss of principal.
